Judith Stangl-Kremser (@judithstkr) 's Twitter Profile
Judith Stangl-Kremser

@judithstkr

MD-PhD, OSU Urology

ID: 1387470138023231495

linkhttps://www.linkedin.com/in/judith-stangl-kremser-40a4b5b3/ calendar_today28-04-2021 18:13:59

57 Tweet

123 Followers

263 Following

European Association of Urology (EAU) (@uroweb) 's Twitter Profile Photo

Penile cancer is a rare disease with an incidence that is rising globally. ASCO collaborated with the European Association of Urology (EAU) to develop new guidelines. Oscar Brouwer and Scott Tagawa tell us about it šŸ‘‡ #PenileCancer #EAUGuidelines ascopost.com/issues/april-1…

Penile cancer is a rare disease with an incidence that is rising globally. ASCO collaborated with the European Association of Urology (EAU) to develop new guidelines. 
<a href="/Brouwer_MD_PhD/">Oscar Brouwer</a> and <a href="/DrScottTagawa/">Scott Tagawa</a> tell us about it šŸ‘‡

#PenileCancer #EAUGuidelines 

ascopost.com/issues/april-1…
Susan MacDonald, MD (@smacdonald_md) 's Twitter Profile Photo

Honored to have paired up with my first female mentor within urology Amanda North, Dr. Amanda North from MontefioreUrology to write on the gender gap in promotions in this month's AUANews special issue focusing on diversity, equity, and inclusion. TošŸ‘€: auanews.net/issues/article…

Dr. Jones Nauseef (@drjonesnauseef) 's Twitter Profile Photo

Thrilling to present at #AACR23 our exciting phase I results of 225Ac-J591 anti-#PSMA therapy in mCRPC. This is homegrown Weill Cornell Medicine science, making it extra sweet. Huge thank you to the patients who make clinical research possible & to Scott Tagawa for unrivaled mentorship.

WCM GU Cancer (@wcmgucancer) 's Twitter Profile Photo

.Scott Tagawa presented Weill Cornell Medicine #research at #ASCO23 evaluating the first combination of dual prostate-specific membrane antigen (#PSMA) targeting for metastatic castration-resistant #ProstateCancer: bit.ly/3OXBqQD

.<a href="/DrScottTagawa/">Scott Tagawa</a> presented <a href="/WeillCornell/">Weill Cornell Medicine</a> #research at #ASCO23 evaluating the first combination of dual prostate-specific membrane antigen (#PSMA) targeting for metastatic castration-resistant #ProstateCancer: bit.ly/3OXBqQD
YUO (@suo_yuo) 's Twitter Profile Photo

Please join us in congratulating our YUO Chair Simpa Salami! Dr. Salami is the winner of the Amer. Urol. Assn.’s prestigious Gold Cystoscope Award for his outstanding contributions to the science of genomics for the early detection and treatment of urologic cancers šŸ‘šŸ‘šŸ‘

Please join us in congratulating our YUO Chair <a href="/samsimsal/">Simpa Salami</a>!

Dr. Salami is the winner of the <a href="/AmerUrological/">Amer. Urol. Assn.</a>’s prestigious Gold Cystoscope Award for his outstanding contributions to the science of genomics for the early detection and treatment of urologic cancers šŸ‘šŸ‘šŸ‘
Shahrokh F. Shariat (@drshariat) 's Twitter Profile Photo

FINALLY - what I have been looking forward to prove for 20 years: the detection performance of DRE for PCa is so weak that we can forego this exam. Hope the guidelines take this evidence to stop recommending DRE for PCa screening/early detection. sciencedirect.com/science/articl…

Andres Ricaurte Fajardo (@andresricaurte1) 's Twitter Profile Photo

Excited to share our latest publication on key breakthroughs in one of the most exciting frontiers of precision oncology: PSMA-TRT. Greatful to Drs Samuel Ruder Scott Tagawa and co-authors! Weill Cornell Medicine Radiology WCM GU Cancer Weill Cornell Medicine Meyer Cancer Center šŸ”—: link.springer.com/article/10.100…

Knowuro (@knowuro) 's Twitter Profile Photo

#Urologists often overlook bowel symptoms after RC—especially in younger patients and those with neobladders. These symptoms can seriously impact quality of life. Don’t forget to ask. Don’t forget to manage.

#Urologists often overlook bowel symptoms after RC—especially in younger patients and those with neobladders.

These symptoms can seriously impact quality of life. Don’t forget to ask. 
Don’t forget to manage.